Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -2.56% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.48 | N/A | -2.56% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a commitment to their ongoing clinical trials. They acknowledged the challenges faced in the quarter without providing detailed future guidance.
Management did not provide specific revenue guidance for the upcoming period.
The company is focusing on advancing its clinical programs despite the EPS miss.
Protagonist Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and forward guidance may raise concerns among investors about the company's near-term performance. The stock's reaction reflects cautious sentiment as the company continues to navigate its clinical development efforts.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ABM INDS INC
Mar 9, 2021